Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Honestly, I don't think one has anything do with the other. The sales/distribution methods in Europe are much different than Canada and the US.
I agree, Vascepa has been a bit of a disappointment in Canada. $17-18M in full-year revenue after this many years is pretty disappointing. I wasn't able to listen to the earnings call today, but am hoping to listen to the replay when available.
I think a lot of this goes back to the GIA strategy. HLS is not a big company. They are tiny, and they are boot-strapping it (hence, why they brought in Pfizer originally).
Vascepa in the hands of a BP probably would have gone much differently.
Ziploc, Just tried searching Google patents - very extensive documentation:
https://patents.google.com/patent/WO2023146984A1/en?oq=WO2023146984
Its disappointing that Pfizer is not able to find marketing leverage for Vascepa in Canada primary care !
How will this impact evaluation estimates for other BP's in Europe ??
Its most likely a Bearish sign, neutral at best, and not what I was hoping for !!
I didn't say it was a waste of time and money. I said I don't think that's the direction Sarissa wants to go.
And how can Amarin claim a patent on research they didn't do, using a product that is not even theirs?
I'm not sure why you and Kiwi think this is such a big waste of time and money..... they don't need to chase a migrane indication..... they have the resources to do a quick patent search and if one doesn't exist, apply for the patent and add it to the portfolio for future use.
Published Today: New US Patent Application US 2024/0148683 A1 for the encapsulation of ultra-pure EPA. This is presumably filed to extend the current patent # US 8,642,077 B2 which is set to expire Feb. 4, 2034.
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240148683
Just a reminder of one of the reasons why generic versions of VASCEPA® which are not encapsulated by this patented method may not be as efficacious as the Real Deal! Don’t trust your health and life to oxidized products!
I have to agree with Kiwi on this. Amarin already knows about the migraine issue. They are aware of anything and everything that goes on with IPE.
But I also don't believe that Amarin has the time, resources, or interest to chase new indications that are not central to their goal. I believe Denner wants to focus on getting V rolled out in Europe, finish out the litigation efforts in the U.S. (whatever might come of that), possibly do something with the new formulations (LrEtEPA, MND-2119), and get this thing sold.
The other indications and formulations...colorectal cancer, migraines, FDC, etc. are likely something to be dangled in front of a BP as a future opportunity.
I may be wildly wrong, but there does not seem to be any effort or money being spent on R&D right now, which would be the big indicator that something was going on.
As I have stated previously about the lack of traction in Canada, it was only a matter of time before HLS needed to do something.
Pfizer was responsible for less than $6M in revenue annually, IIRC. They essentially weren't selling anything.
On a more positive note, HLS highlights in Canada included:
Vascepa unit demand increased by 54% compared to Q1 2023.
The number of consistent prescribers2 for Vascepa increased 112% compared to Q1 2023.
Vascepa net revenue was C$4.5 million, up 27% compared to C$3.5 million in Q1 2023.
Here is a summary of Amarin's patents on LR-EtEPA
Abstract of patents WO2023146984
"Lymph-releasing compositions of fatty acids and uses thereof for lymphatic incorporation and systemic disease treatment
Abstract
Provided are compositions comprising one or more polyunsaturated fatty acids or derivatives thereof, a source of phospholipid, and optionally one or more additional emulsifiers, as well as methods of using the same to treat various diseases. In some embodiments, provided is a lymph-releasing composition of eicosapentaenoic acid ethyl ester (LR-EtEPA) and methods of using the same to increase EPA uptake in tissues and to treat various diseases including cardiopulmonary diseases, renal diseases, neurological diseases, and CANCER."
HLS in Canada has terminated their agreement with Pfizer effective May 1st!!
"We have been closely examining the performance of our go-to-market model in primary care. We have concluded that the ROI for this model remains unprofitable and, despite best efforts, there are not enough signs of improvement to justify continuing at our current level of investment. As a result, we have provided Pfizer with a notice of termination of the Agreement between the two companies. We are working with them on an orderly wind down and transition back to HLS of all primary care related activities which we expect will be completed during the second half of 2024. We thank Pfizer for the commitment and effort that they have made towards trying to make this go-to-market model successful."
Yep, could have used VASCEPA 16 years ago when I had my prostate removed!
You are by far the best advocate for AMRN.
Captain,
Thank you for keeping us abreast on PREPARE RCT (PRevention Using EPA Against coloREctal).
As a reminder, Amarin’s Form 10-K 2022 for the year ending December 31, 2021 asserts that the Company "owns" "one additional patent related to the use of VASCEPA to treat prostate cancer with a term that expires in 2037."
Trust me, there’s going to be enough heart disease to go around for everybody.
Then they better get moving, don't you think! ...... they just need to apply for it Kiwi...... get the app in first...... they won't even own the company by the time it's approved so who cares? BP will follow up.
Nope ...good news for the new weight loss drugs
Now if Vascepa could be proven to reduce obesity ...then you're talking
Kiwi
Good news for the future of Amarin and Vascepa I guess.
https://www.nbcnews.com/health/heart-health/adults-us-heart-diabetes-syndrome-risk-research-rcna151215
Ram. it typically takes 1-5 yrs to get a patent on a drug . You're dealing with prior art and USPTO actions .
IIRC in the 2010 / 2011 period the patent office originally rejected the Marine patent . Eventually it was approved because AMRN could prove that Vascepa ( AMR101 at the time ) was DEVOID of DHA . Epadel by contrast has up to 10% DHA .
Poster North may have a better memory of this period.
AMRN doesn't have this time if they continue on their current path and especially if they use $50m on a share buyback.
The reality is that revenue in the US is crashing and revenue growth in the EU is minuscule .
And so far mgt has yet to come up with an effective plan to convince the market , they can change that .
Which is why the PPS is under $1.
JMO
Kiwi
Ramfan, Does anyone else have a method of use patent, that covers icosapent ethyl, for migraine treatment?
Sleven,
Why wouldn't they spend time and money on a patent....... it's not that much time and it's not that much money. They don't have to do any lengthy study either..... just get the patent and add it to your patent portfolio to increase the value of the company.
I hope that management is well informed and aware of the opportunities that this study will provide.
Because Dr Ketchum probably knows this already ...and knows AMRN will not spend time and $ on pursuing this since for one thing they would need to prove it better than an EPA/DHA combination .
So, why are you telling me all this? These things I already know. Again my point to relaying this to Amarin is to inform them of a possible patent they could get priority on. Indications which already have studies on the drug you own are low hanging fruit. Don't let the competition snag an IP that you should get the first crack at.
Capt. I believe thats a lot of Prior Art regarding Omega 3's and migraines ...so patent protection might be a challenge.
The exclusivity route ...see previous posts .
Great graphics tho
Kiwi
So I'll answer my own question about lack of patent protect for the migraine indication...exclusivity is an option
There's a plethora of indications that could be studied. What would I have Amarin do? Figure out which indications are hanging fruit and get those patent applications submitted. My reason for pointing these things out to them is because I'm not sure they're even aware of this stuff. Maybe they'll see the good work I do and offer me a job in PR? lol
CaptBeer
Yet another reason for the 10 % drop for us When will it ever end ? I mean OMG we cannot even be at 1 dollar so sad . Less then 2 million shares traded what happens when its 40/50 million shares ?
Michael
EPA is a med that needs development ASAP, not only for the CVD indication, but also for several other indications...If Amarin is unable to perform this task, Amarin should be sold to a BP that has the necessary assets to do it.
My apologies for my mistake. I was looking at JAMA Network link, not the link you had referred to.
JR, You are an Ok guy 'some days' - when your not focusing on Sarissa and Denner 'cheating everyone' in the market 🙂
---------------------------------
Here trying to solve the confusion - olive oil / EPA Vascepa for North - 'no spring hare' !
Capt. What would you have AMRN do with this info ?
AMRN doesn't have any patents covering composition or method of action for treating migraines that I'm aware of .
The trial was run using Epadel ...and it only enrolled 70 people using a drug not FDA regulated
ralphey, You seriously are in need of psychological help.
You spending time on a random financial forum - where you clearly have no idea of what is actually going on - calls for a serios mental problem !
--------------------------------
You go find a qualified psychiatrist - who know which best drugs to help you - and in a few months - you will again be able to appreciate being alive 🙂
Captain, Let me know if you get a response.
Thanks.
Sleven,
yep. I sent this link and my slides to Amarin. They need to get eyes on this. The CRC study is another one that they need to move on.
Captain,
https://www.sciencedirect.com/science/article/pii/S0889159124003003
Journal publication.
Sleven,
The Treatment Arm consisted of:
(2) 1g capsules of EPA (900mg), DHA (10mg), other FA's (90mg) * note although not specifically named this is the formulation of EPADEL.
The Placebo Arm was 100% Soybean Oil
DYK that EPA significantly reduces the number of migraine attacks and their severity. Who knew?https://t.co/SLwMWHqegK
— Mike Everts (@GeoWizz_) May 8, 2024
@Amarincorp @SABOURETCardio @DLBHATTMD @drpablocorral @mmillermd1 @VietHeartPA @MarkBrady2014 pic.twitter.com/tSz3wGPuMr
CCI.
Clown contrarian indicator
Yeah, what’s with the beat down today?
Ralphey,
You are bitter. We are all sad and disappointed, but it serves no purpose to get bitter.
Looks like everyone that wanted a lower PPS is Happy Happy Happy !!!
Michael
Probably. Thanks.
He may be looking at the study that I posted, which WAS referring to a study on olive oil consumption and dementia
Capt clearly states EPA in his message and accompanying chart. Olive oil is not mentioned.
I see no mention of Epadol in my print of study, only olive oil.
North, I believe it is 1.8 gr of EPADEL EPA per day, not olive oil.
Nice graph summarizing the benefits of 1.8 grams of olive oil per day, or maybe 2 capsules of (more?) expensive Vascepa per day. I have been taking unknown weights of olive oil for much longer than 4 grams of V per day. What would Chinese citizens be persuaded to take?
Over 1 billion people worldwide suffer from migraines. A new trial completed in Taiwan using 1.8g EPA/day vs. placebo demonstrated significant improvement in frequency of attacks and in the severity of those events. Another huge potential Indication for VASCEPA/VAZKEPA.
Here's a summary slide I put together showing the Primary Outcome Measures:
Too good to be true ! AMRN that wonderful soap opera . AS you will recall the stock was $1 in 2007. A lot has happened since then . The desperate housewives were jilted by the loser Thero who absconded with all of their money. They fell in love with AMRN who repeatedly pumped and dumped them yet they always come back for more. The fat lady is singing but the pudding is no longer mud. Its pink ! Yes Momma gonna make PINK SHEET PUDDING ! Drum Roll Paaaaleeeeze ta dum tad dum ta dum BOOM Thats right the stock is worth 94 pennies less than what it was in 2007 !! Tune in next week for the same story line as the desperate housewives of Investors hub get pumped and dumped all along screaming that its a wonderful buying opportunity !!
Followers
|
1112
|
Posters
|
|
Posts (Today)
|
45
|
Posts (Total)
|
424513
|
Created
|
03/12/07
|
Type
|
Free
|
Moderators ziploc_1 zmanindc golf stud Number sleven |
AMARIN TICKER RELATED LINKS
Amarin Webpage
NASDAQ AMRN Quote
Y! Finance AMRN Landing Page
Seeking Alpha AMRN Landing Page
FinViz AMRN Landing Page
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |